bioLIVE, the new bioprocessing and manufacturing event running alongside this year’s CPhI Worldwide, organized by UBM, a company which in June 2018 combined with Informa PLC to become a leading B2B information services group and the largest B2B Events organizer in the world, announces the initial findings of the world’s first ever biopharma league table, which evaluates the reputations of major bio manufacturing countries across a number of characteristics which they scored between 1-10.
bioLIVE is a new event with an exhibition and a live content stage, focusing on large molecule Biopharma and more specifically on manufacturing and processing. This new event is designed to be an unique platform connecting biotechs, big pharma and service providers across the large molecule value chain.
The biopharma league table follows the launch of the small molecule pharma league table introduced last year.
The provisional results, included in the biopharma league table suggest that global industry executives and pharmaceutical companies perceived the United States as the top ranking nation for all major categories – ‘knowledge of professionals’ (8.2); ‘ability to meet future capacity’ (7.9); ‘bio innovation’ (8.0); ‘quality of processing’ (8.1) – and, perhaps more surprisingly, ‘growth potential’, ahead of emerging bio hubs in China, Ireland, and Singapore, as well as established rivals in the UK, Japan and Germany. 
Most surprising are the results of China, a country that has seen a well-documented surge in both innovative biotech start-ups and bioprocessing and manufacturing companies. The results show that the country’s reputation in biologics is still far behind the more established players. China scored below 6 for ‘bio innovation’ and ‘quality of biological manufacturing’ – bottom in both respective league tables. This suggests that perception may lag behind reality.
“If we look at quality and innovation, both important attributes for advancing bioprocessing technologies, the US, Germany and Japan are ranked highest, followed by several other European countries, where biomanufacturing is a mature industry,” commented bioLIVE expert, Dawn M. Ecker of BioProcess Technology Consultants.
“China and India, both burgeoning markets for biologics, were not ranked as high for innovation. This perception may relate to the still developing biologics and bioprocessing industry in these regions, coupled with the knowledge of their existing reputations for mass production of generics,” Ecker added.
The full findings from 500 companies will be published during bioLIVE which will be held October 9-11, 2018 in Madrid, Spain.
According to publication, Spain, the host nation, is scoring just above 6 for all categories. This is significantly behind the other four major European economies, as well as Ireland. In fact, recent training initiatives by Ireland’s NIBRT (National Institute for Bioprocessing Research) may be paying dividends as the country scored highly on ‘knowledge of bio professionals’ (7.2), and second only to Germany in terms of ‘growth potential’ (7.0) amongst EU countries.
Ecker however felt Ireland should have performed even more strongly.
“Surprisingly, Ireland did not score as high as other European countries, despite the strong presence of biopharma manufacturing and the significant number of biomanufacturing facilities to be built here in the coming years. In this case, perception may be related to the increased demand for skilled staff, with not enough skilled staff to support the projected additional capacity growth,” Ecker explained.
Overall, when performance across all categories is analyzed, the USA (7.88), Germany (7.49) and Japan (7.46) again appear as tier one nations – mirroring the results in small molecule manufacturing – with Sweden (6.95) and the United Kingdom (6.91), ranking as the best of the rest.
The most notable difference between small and large molecule rankings was amongst the performance of mid to high ranking countries with Sweden (6.95), Singapore (6.54), and notably, South Korea (6.69), which is home of a growing biopharma sector including Samsung Biologics – performing comparably to France (6.72), Spain (6.51), Italy (6.55) and Ireland (6.81) in terms of biologics.
India (6.31) and China (6.29) were adrift at the foot of the table – however, if Indian participants were excluded, India would finish behind China given the larger number of Indian participants in the survey data.
“We are increasingly seeing a lot more bio professionals at CPhI and to announce the launch of our new bio processing and manufacturing event we wanted to explore what role reputation and perception may play,” noted Rutger Oudejans, Brand Director at bioLIVE.
“With bioprocessing and outsourcing set to rise quickly over the next few years, partnerships and investment decisions may well be impacted by the perceived status of nations verses the reality of their capabilities. We have also seen across all economies a shortage of qualified personal so certainly initiatives like NIBRT who are giving a couple of session at this year’s event will become increasingly important. Overall, our results suggest that whilst the US is clearly ahead, the majority of countries scored between 6 and 7, and it was very, very even. It suggests it’s a very level playing field in terms of business opportunities and that attendees at bioLIVE will be open to working with a very diverse supply chain,” Oudejans concluded.